北美老年性黄斑变性 (AMD) 疾病市场 – 行业趋势和 2029 年预测

市场分析和见解

北美老年性黄斑变性 (AMD) 疾病市场受到诸多因素的推动，例如老年人口增加、老年性黄斑变性 (AMD) 疾病患病率上升、产品线产品需求增加以及研发投入增加等，这些因素都推动了市场增长。目前，发达国家和新兴国家的医疗保健支出都有所增加，这有望为制造商开发新的创新产品创造竞争优势。

由于人口老龄化和预期寿命延长，发达国家老年性黄斑变性的患病率预计会增加。据估计，近 60% 的患者在出生后不久就会出现严重的视力障碍。这种疾病会导致患者眼睛中央视力模糊。发达国家对老年性黄斑变性 (AMD) 疾病治疗和诊断的需求有所增加。然而，治疗和程序的高成本以及政府对产品审批的严格规定预计将阻碍老年性黄斑变性 (AMD) 疾病市场的增长。

北美老年性黄斑变性 (AMD) 疾病市场具有支持性，旨在减缓疾病的进展。Data Bridge Market Research 分析，北美老年性黄斑变性 (AMD) 疾病市场在 2022 年至 2029 年的预测期内将以 8.0% 的复合年增长率增长。

市场定义

Age-related macular degeneration (AMD) is an eye disease that can cause damage to the macula part of the eye that controls sharp and straight-ahead vision. This leads to blurring central vision. Vision loss can be caused by abnormal blood vessel growth. Sometimes abnormal new blood vessels grow from the choroid under and into the macula. The choroid is the layer of blood vessels between the retina and the outer, firm coat of the eye (sclera). These abnormal blood vessels may leak fluid or blood, interfering with the retina's function. Macular degeneration is common in aging people. Other reasons for the rising of procedures can be defined by the increasing aging people causes and the requirement for healthcare facilities, including treatment for patient-friendly techniques for diagnosis where the medical requirements are maximum, which can further decrease the burden on healthcare facilities.

The diagnosis and treatment of age-related macular degeneration (AMD) disease consist of various techniques that allow diagnosis of the disease after the approval of the product. The treatment for the disease is recently approved, which supports the market growth. However, these treatments are expensive and not available to all patients.

North America Age-Related Macular Degeneration (AMD) Disease Market Dynamics

Drivers

• Rising geriatric population

The world’s geriatric population is increasing at a rapid rate. With the increasing age comes a reciprocal increase in the number of elderly patients due to the rising prevalence of chronic disease. Age is a severe risk factor for any disease progression as age is an essential parameter that affects fundamental biological mechanisms. Therefore, aging is one of the risk factors for the North America incidence of early AMD. -related macular degeneration (AMD) can cause damage to the macula part of the eye. This leads to blur central vision. It can cause irreversible blindness and is the leading cause of visual impairment in the elderly people.

Macular degeneration is more common in aging people. The diagnosis of disease is possible at various stages and number of genetic testing and retinal imaging are some of the techniques for the detection of disease. The diagnosis of the disease is conducted mainly by optical imaging techniques and other standard process. Thus, the increasing rate of the geriatric population is expected to drive the growth of the North America age-related macular degeneration (AMD) disease market growth.

• Increasing Prevalence of Age-Related Macular Degeneration (AMD) Disease

The demand for age-related macular degeneration (AMD) disease treatment and diagnostic has been increased more in the developed countries. These countries had reimbursement policies for age-related macular degeneration (AMD) disease market along with that increasing prevalence of genetic diseases.

Thus, it signifies that increasing prevalence of age-related macular degeneration (AMD) disease is expected to drive the North America age-related macular degeneration (AMD) disease market growth.

Opportunity

•  Rising Research and Development 

Research and development is a prerequisite to modifying the treatment intended to treat different kinds of patients. The demand for age-related macular degeneration (AMD) treatment and procedures increasing worldwide involving every country North America. This is why the companies are continuously focusing on research and development in order to achieve success in providing effective treatment to patients and healthcare workers.

The effects can be seen only for individuals in certain ways that include effective potentiating factors such as the disease evolves, vision becomes progressively more compromised, the retinal tissue degenerates, and suffering permanent damage.

As the companies are constantly engaged in developmental activities more innovative products are launched in the market. This thus signifies that increasing research and development is expected as an opportunity for the North America age-related macular degeneration (AMD) disease growth. The various programs and decisions taken by the government around the world for giving the best treatment to their population is the major factor that is expected to increase the demand and will act as an opportunity for the North America age-related macular degeneration (AMD) disease market.

Restraint/Challenge

• High cost of aesthetic surgical procedures

The cost of the product plays a major factor in the market. In the age-related macular degeneration (AMD) disease, it is generally observed that they are highly sophisticated, need to be precise, and other specifications increase the product's cost. Moreover, the cost associated with treatment for a longer duration is quite difficult for an average-income person to afford. Utilizations of critical care and intensive care unit services are increasing worldwide, along with their expensive cost is a major concern in the current healthcare system.

Patients with degeneration disorder are commonly required to have long treatment with frequent monetarization and other usage leading to consuming a significant amount of healthcare resources. Due to this, most patients who cannot afford long-term economic costs get discharged in the initial stages of treatment.  But this increases the possibilities and susceptibilities for new complications in the diagnosis which demands additional healthcare resources and treatment. As the cost of innovative and advanced products is high, the cost of the treatment proportionally gets escalated, due to which high cost associated with age-related macular degeneration (AMD) disease treatment and diagnosis is expected to restrain the North America age-related macular degeneration (AMD) disease market growth.

Recent Developments

• 2022 年 1 月，Genentech, Inc 宣布美国食品药品监督管理局 (FDA) 已批准 Vabysmo (faricimab-svoa) 用于治疗湿性 AMD 和 DME。这将有助于该公司在预测期内将该产品推向市场。
• 2022 年 4 月，Graybug Vision Inc. 宣布，该公司已在视觉和眼科研究协会 (ARVO) 年会上展示了 GB-401 治疗原发性开角型青光眼 (POAG) 的海报展示临床前数据。这将增加该药物在市场上的安全性和评估机会。

北美老年性黄斑变性 (AMD) 疾病市场细分

北美老年性黄斑变性 (AMD) 疾病市场根据类型、最终用户和分销渠道分为三个显著的细分市场。细分市场之间的增长有助于您分析利基增长点和进入市场的策略，并确定您的核心应用领域和目标市场的差异。

类型

• 干性 AMD
• 湿性黄斑变性

根据类型，北美年龄相关性黄斑变性 (AMD) 疾病市场分为干性 AMD 和湿性 AMD。

最终用户

• 医院
• 专科诊所
• 门诊手术中心
• 家庭医疗保健
• 其他的

根据最终用户，北美年龄相关性黄斑变性 (AMD) 疾病市场分为医院、专科诊所、门诊手术中心、家庭医疗保健和其他。

分销渠道

• 零售销售
• 直接招标

根据分销渠道，北美年龄相关性黄斑变性 (AMD) 疾病市场分为零售和直接招标。

年龄相关性黄斑变性 (AMD) 疾病市场区域分析/见解

对年龄相关性黄斑变性 (AMD) 疾病市场进行了分析，并按上述类型、最终用户和分销渠道提供了市场规模洞察和趋势。

年龄相关性黄斑变性（AMD）疾病报告涵盖的国家包括美国、加拿大和墨西哥。

由于发展中地区的技术进步日益加快，美国有望占据主导地位。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了北美品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

竞争格局和老年性黄斑变性 (AMD) 疾病市场份额分析

北美老年性黄斑变性 (AMD) 疾病市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、北美业务、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对老年性黄斑变性 (AMD) 疾病市场的关注有关。

该市场的一些参与者包括诺华公司、拜耳公司、安斯泰来制药公司、REGENXBIO 公司、Ionis Pharmaceutics、Ocugen 公司、强生服务公司、IVERIC bio、MeiraGTx Limited、Adverum Biotechnologies 公司、Graybug Vision 公司、Kodiak Sciences 公司、基因泰克公司等。

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、北美与地区和供应商份额分析。如有进一步询问，请要求分析师致电。

SKU-68460